Related Experiment Video
Updated: Oct 14, 2025

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice
Published on: February 3, 2016
Fungi: Friend or Foe? A Mycobiome Evaluation in Children With Autism and Gastrointestinal Symptoms
Jane Alookaran1, Yuying Liu1, Thomas A Auchtung2
1Department of Pediatric Gastroenterology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.
Abstract:
Gastrointestinal (GI) symptoms often affect children with autism spectrum disorders (ASD) and GI symptoms have been associated with an abnormal fecal microbiome. There is limited evidence of Candida species being more prevalent in children with ASD. We enrolled 20 children with ASD and GI symptoms (ASD + GI), 10 children with ASD but no GI symptoms (ASD - GI), and 20 from typically developing (TD) children in this pilot study. Fecal mycobiome taxa were analyzed by Internal Transcribed Spacer sequencing. GI symptoms (GI Severity Index [GSI]), behavioral symptoms (Social Responsiveness Scale -2 [SRS-2]), inflammation and fungal immunity (fecal calprotectin and serum dectin-1 [ELISA]) were evaluated. We observed no changes in the abundance of total fungal species (alpha diversity) between groups. Samples with identifiable Candida spp. were present in 4 of 19 (21%) ASD + GI, in 5 of 9 (56%) ASD - GI, and in 4 of 16 (25%) TD children (overall P = 0.18). The presence of Candida spp. did not correlate with behavioral or GI symptoms (P = 0.38, P = 0.5, respectively). Fecal calprotectin was normal in all but one child. Finally, there was no significance in serum dectin-1 levels, suggesting no increased fungal immunity in children with ASD. Our data suggest that fungi are present at normal levels in the stool of children with ASD and are not associated with gut inflammation.
Insights
This study found that the presence of fungi, including Candida species, in the gut of children with autism spectrum disorder (ASD) is not significantly different from typically developing children and does not correlate with gastrointestinal symptoms.
Area of Science:
- Microbiology
- Pediatrics
- Neurodevelopmental Disorders
Background:
- Gastrointestinal (GI) symptoms are common in children with autism spectrum disorder (ASD) and are linked to alterations in the gut microbiome.
- Limited research suggests a potential increase in Candida species in children with ASD, but evidence remains scarce.
Purpose of the Study:
- To investigate the prevalence and abundance of fecal fungi, specifically Candida species, in children with ASD and GI symptoms compared to those with ASD but no GI symptoms and typically developing children.
- To explore the association between fecal mycobiome composition, GI symptoms, behavioral symptoms, and markers of gut inflammation and fungal immunity in children with ASD.
Main Methods:
- Fecal samples from children with ASD and GI symptoms (ASD + GI), ASD without GI symptoms (ASD - GI), and typically developing (TD) children were analyzed for fungal taxa using Internal Transcribed Spacer sequencing.
- Evaluated GI symptom severity (GSI), behavioral symptoms (SRS-2), fecal calprotectin (inflammation marker), and serum dectin-1 (fungal immunity marker) via ELISA.
Main Results:
- No significant differences were observed in the overall abundance of fungal species (alpha diversity) across the three groups.
- Candida species were detected in 21% of ASD + GI, 56% of ASD - GI, and 25% of TD children, with no statistically significant difference between groups.
- The presence of Candida species did not correlate with GI or behavioral symptoms, nor with fecal calprotectin or serum dectin-1 levels, indicating no increased fungal presence or immunity associated with ASD.
Conclusions:
- Fungal presence in the stool of children with ASD appears to be at normal levels and is not associated with GI symptoms or gut inflammation.
- These findings suggest that Candida overgrowth is unlikely to be a primary driver of GI issues in children with ASD.
Related Concept Videos
Fungal Phylum Microsporidia
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Fungal Group Zygomycota
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.

